Literature DB >> 21147941

MAO inhibitors: risks, benefits, and lore.

Molly Wimbiscus1, Olga Kostenko, Donald Malone.   

Abstract

Monoamine oxidase (MAO) inhibitors were the first antidepressants introduced, but their use has dwindled because of their reported side effects, their food and drug interactions, and the introduction of other classes of agents. However, interest in MAO inhibitors is reviving. Here, we discuss their use, risks, and benefits in clinical medicine.

Mesh：

Substances：

Year:  2010        PMID： 21147941     DOI： 10.3949/ccjm.77a.09103

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  31 in total

1.  Amino oxidase activity of hepatopancreas preparations from the octopus Bathypolypus arcticus.

Authors:  I N Basova; O V Yagodina
Journal:  Dokl Biochem Biophys       Date:  2012-03-15       Impact factor: 0.788

2.  Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.

Authors:  Syed Ahmad; Mark A Hughes; Li-An Yeh; John E Scott
Journal:  J Biomol Screen       Date:  2012-04-24

Review 3.  Safety considerations in drug treatment of depression in HIV-positive patients: an updated review.

Authors:  Crystal C Watkins; Andrew A Pieper; Glenn J Treisman
Journal:  Drug Saf       Date:  2011-08-01       Impact factor: 5.606

4.  De novo microdeletion of Xp11.3 exclusively encompassing the monoamine oxidase A and B genes in a male infant with episodic hypotonia: a genomics approach to personalized medicine.

Authors:  Ryan E O'Leary; Jean C Shih; Keith Hyland; Nancy Kramer; Y Jane Tavyev Asher; John M Graham
Journal:  Eur J Med Genet       Date:  2012-02-03       Impact factor: 2.708

5.  Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination.

Authors:  Joshua A Israel
Journal:  Prim Care Companion CNS Disord       Date:  2015-12-10

6.  Clinically significant psychotropic drug-drug interactions in the primary care setting.

Authors:  Brett A English; Marcus Dortch; Larry Ereshefsky; Stanford Jhee
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

7.  Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.

Authors:  Shikha Gaur; Mitchell E Gross; Chun-Peng Liao; Bin Qian; Jean C Shih
Journal:  Prostate       Date:  2019-01-28       Impact factor: 4.104

8.  In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.

Authors:  S Flanagan; K Bartizal; S L Minassian; E Fang; P Prokocimer
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

Review 9.  Current place of monoamine oxidase inhibitors in the treatment of depression.

Authors:  Kenneth I Shulman; Nathan Herrmann; Scott E Walker
Journal:  CNS Drugs       Date:  2013-10       Impact factor: 5.749

Review 10.  A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths.

Authors:  Peter Kenneth Gillman
Journal:  J Neural Transm (Vienna)       Date:  2018-09-25       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.